Top entities: ImmunityBio, Bronstein, Gewirtz & Grossman, LLC, Patrick Soon-Shiong.

What category does this event fall under?

Regulatory — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 10, 2026. Coverage continues to evolve.

Regulatory class action

ImmunityBio faces Anktiva class action

Q: When did this event occur?

First reported May 03, 2026; last updated May 10, 2026.

Q: What is the market impact?

Direct. The class action lawsuit against ImmunityBio for alleged misrepresentation of Nogapendekin alfa inbakicept's capabilities is likely to negatively impact ImmunityBio's stock price and investor confidence.

Analysis based on 8 articles · First reported May 03, 2026 · Last updated May 10, 2026

Sentiment

-50

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The class action lawsuit against ImmunityBio for alleged misrepresentation of Nogapendekin alfa inbakicept's capabilities is likely to negatively impact ImmunityBio's stock price and investor confidence. It also highlights the ongoing scrutiny of public company disclosures in the biotechnology sector.

Biotechnology Legal Services

Event Summary

A class action lawsuit has been filed against ImmunityBio, Inc. and certain of its officers, including Defendant Soon-Shiong, by the investor-rights law firm Bronstein, Gewirtz & Grossman, LLC. The lawsuit alleges that ImmunityBio made materially false and misleading statements regarding the capabilities of Nogapendekin alfa inbakicept, leading to investor losses. The class period for affected investors is between January 19, 2026, and March 24, 2026. Investors are encouraged to join the case, with a deadline of May 26, 2026, to request appointment as lead plaintiff.

Key Actions

100 Bronstein, Gewirtz & Grossman, LLC filed lawsuit ImmunityBio

Entities Involved

stock

ImmunityBio

ImmunityBio is the defendant in a class action lawsuit alleging that its officers made materially false and misleading statements regarding Nogapendekin alfa inbakicept's capabilities, leading to investor losses.

Importance 100 Sentiment -70

priv

Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman, LLC is the investor-rights law firm that filed the class action lawsuit against ImmunityBio and is representing the investors.

Importance 80 Sentiment 50

per

Patrick Soon-Shiong

Defendant Soon-Shiong is alleged to have materially overstated Nogapendekin alfa inbakicept's capabilities, which is a central claim in the class action lawsuit against ImmunityBio.

Importance 70 Sentiment -60

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard